Standard BioTools reported second quarter revenue of $20.1 million, down 7.6% year-over-year and missing analyst estimates of $20.8 million. The company reported a net loss per share from continuing operations of $0.06, missing expectations of a $0.01 loss. In light of its pending merger with Treeline Biosciences, the company has withdrawn its full-year 2026 revenue outlook.
Key Highlights
- Q2 revenue came in at $20.1 million, a 7.6% decrease from the prior year, attributed to continued capital constraints in end-markets and uncertainty in US academic spending.
- Adjusted EBITDA loss significantly narrowed by 84% year-over-year to $2.5 million from a loss of $16.1 million, which management attributed to cost discipline and restructuring actions.
- The company withdrew its full-year 2026 revenue outlook, citing the pending merger with Treeline Biosciences which is anticipated to close before the end of 2026.